• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

System of Criteria for Treatment Evaluation of Acromegaly in Bulgaria.

作者信息

Krastev Evgeniy, Tcharaktchiev Dimitar, Markov Emanuil

机构信息

Faculty of Mathematics and Informatics, Sofia University St. Kliment Ohridsky, Bulgaria.

Department of Medical Informatics, Medical University Sofia, Bulgaria.

出版信息

Stud Health Technol Inform. 2020 Jun 26;272:413-416. doi: 10.3233/SHTI200583.

DOI:10.3233/SHTI200583
PMID:32604690
Abstract

Acromegaly is a rare endocrine disorder caused by excessive and longstanding secretion of growth hormone (GH) by the pituitary somatotroph and resulting from this overproduction of insulin-like growth factor-1 hormone (IGF-1) by the liver. There are few registers and rather limited clinical data about acromegaly treatment. The analysis of acromegaly data is rarely subject to a system of criteria for evaluating acromegaly treatment. The novelty of this paper is that it presents a real- life practice case study about the implementation results of such a system in Bulgaria. The case study analysis illustrates a clinical information approach to manage thousands of records in the Bulgarian Acromegaly Database. The here reported results provide evidence about the difficulties in maintaining both GH and IGF-1 levels inside their reference values in acromegaly treatment. Ongoing research extends the evaluation results by enabling semantic interoperability between acromegaly databases based on openEHR specification.

摘要

相似文献

1
System of Criteria for Treatment Evaluation of Acromegaly in Bulgaria.
Stud Health Technol Inform. 2020 Jun 26;272:413-416. doi: 10.3233/SHTI200583.
2
Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.肢端肥大症患者经垂体手术后,体重指数和胰岛素样生长因子 1 是导致生长激素和胰岛素样生长因子 1 水平不一致的危险因素。
J Formos Med Assoc. 2018 Jan;117(1):34-41. doi: 10.1016/j.jfma.2017.02.014. Epub 2017 Mar 21.
3
Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.分泌生长激素释放激素的神经内分泌肿瘤:病理生理与临床方面
Pituitary. 2006;9(3):221-9. doi: 10.1007/s11102-006-0267-0.
4
Hormonal diagnosis of GH hypersecretory states.生长激素分泌过多状态的激素诊断。
J Endocrinol Invest. 2003;26(10 Suppl):27-35.
5
Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.人生长激素瘤中生长激素和1型胰岛素样生长因子受体的表达降低以及生长激素受体可能突变的分析
Clin Endocrinol (Oxf). 2003 Sep;59(3):328-38. doi: 10.1046/j.1365-2265.2003.01851.x.
6
Dynamic tests and basal values for defining active acromegaly.用于定义活动性肢端肥大症的动态试验和基础值
Neuroendocrinology. 2006;83(3-4):200-4. doi: 10.1159/000095528. Epub 2006 Oct 13.
7
Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.采用生长激素分泌敏感指标对60例肢端肥大症术后患者的疾病状态进行评估。
J Clin Endocrinol Metab. 1998 Nov;83(11):3808-16. doi: 10.1210/jcem.83.11.5266.
8
Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly.生长激素释放激素(GHRH)拮抗剂对过表达人GHRH基因的转基因小鼠(肢端肥大症动物模型)生长激素(GH)和胰岛素样生长因子I水平的影响
Endocrinology. 1997 Nov;138(11):4536-42. doi: 10.1210/endo.138.11.5498.
9
Are there alternative tests for diagnosis of acromegaly?是否有其他诊断肢端肥大症的检查方法?
J Endocrinol Invest. 2005;28(11 Suppl International):73-4.
10
Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia.肢端肥大症合并2型糖尿病,在血糖控制不佳的情况下胰岛素样生长因子-1(IGF-1)水平正常。
Endocr J. 2007 Aug;54(4):537-41. doi: 10.1507/endocrj.k06-083. Epub 2007 Jun 13.